文献速递肝病

临床-遗传风险评分预测肝硬化患者肝性脑病的开发与验证

Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该研究纳入4家医院门诊的600例肝硬化患者并随访至少5年,基因分型60个候选单核苷酸多态性及GLS启动子微卫星,构建结合遗传背景与临床指标的肝性脑病风险评分并在内外队列验证。

要点

  • rs601338、rs5743836、rs2562582、rs313853及GLS微卫星独立预测显性肝性脑病发生与严重程度。
  • 临床-遗传风险评分结合胆红素、白蛋白、遗传评分及既往显性肝性脑病发作。
  • 低危组1年和5年肝性脑病风险分别为5%和12%,高危组分别为36%和48%。

核心结论

  • 遗传背景影响显性肝性脑病风险与严重程度,临床-遗传风险评分可用于预测肝硬化患者显性肝性脑病。

研究设计与样本

  • 纳入4家医院门诊的600例肝硬化患者,随访至少5年直至肝性脑病发作、肝移植或死亡。
  • 对60个候选单核苷酸多态性及GLS基因启动子区微卫星进行基因分型,采用竞争风险分析构建评分并做内部与外部验证。

主要发现

  • rs601338(FUT2)、rs5743836(TRL9)、rs2562582(SLC1A3)、rs313853(SLC1A5)及GLS微卫星独立预测显性肝性脑病发生与严重程度并纳入遗传评分。
  • 竞争风险分析显示胆红素(sHR 1.30 [1.15-1.48],P < 0.001)、白蛋白(sHR 0.90 [0.86-0.93],P < 0.001)、遗传评分(sHR 1.90 [1.57-2.30],P < 0.001)及既往显性肝性脑病发作(sHR 2.60 [1.57-4.29],P < 0.001)与随访期间肝性脑病发作独立相关。
  • 模型内部验证C-index为0.83,外部验证C-index为0.74。
  • 低危组1年和5年肝性脑病风险分别为5%和12%(log-rank 92.1;P < 0.001;log-rank 124.1;P < 0.001),高危组分别为36%和48%。

临床怎么用

  • 临床-遗传风险评分结合遗传背景、白蛋白、胆红素及既往显性肝性脑病发作,可用于预测肝硬化患者显性肝性脑病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We aimed to define the impact of the genetic background on overt hepatic encephalopathy (HE) in patients with liver cirrhosis by developing a combined clinical-genetic risk score. METHODS: Patients suffering from liver cirrhosis from the outpatient clinics of 4 hospitals (n = 600) were included and followed up for at least 5 years until HE bouts, liver transplant, or death. Patients were genotyped for 60 candidate single nucleotide polymorphisms together with the microsatellite in the promoter region of the gene GLS. RESULTS: Single nucleotide polymorphisms rs601338 (FUT2), rs5743836 (TRL9), rs2562582 (SLC1A3), rs313853 (SLC1A5), and GLS microsatellite did predict independently the incidence and severity of overt HE and were included as genetic score. Competing risk analysis revealed that bilirubin (subhazard ratio [sHR] 1.30 [1.15-1.48], P < 0.001), albumin (sHR 0.90 [0.86-0.93], P < 0.001), genetic score (sHR 1.90 [1.57-2.30], P < 0.001), and previous episodes of overt HE (sHR 2.60 [1.57-4.29], P < 0.001) were independently associated to HE bouts during the follow-up with an internal (C-index 0.83) and external validation (C-index 0.74). Patients in the low-risk group had 5% and 12% risk of HE at 1 (log-rank 92.1; P < 0.001) and 5 (log-rank 124.1; P < 0.001) years, respectively, whereas 36% and 48% in the high-risk group. DISCUSSION: The genetic background influenced overt HE risk and severity. The clinical-genetic HE Risk score, which combined genetic background together with albumin, bilirubin, and previous episodes of overt HE, could be a useful tool to predict overt HE in patients with cirrhosis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Gil-Gómez A, Ampuero J, Rojas Á, et al. Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. Am J Gastroenterol. 2021. PMID: 33852451. doi:10.14309/ajg.0000000000001164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。